Work

Supplementary Figure 5 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia

Year: 2026

Type: supplementary-materials

Abstract: (A) Tables showing death percentage of T-ALL primary cells treated with combinations of ziftomenib and temuterkib (ERK inhibitor) or JNJ-7706621 (CDK1/2 inhibitor). (B) Synergy plot of T-ALL primary cells treated with ziftomenib and temuterkib.

DOI: 10.1158/1535-7163.33151985

Authors: Kathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, Arjun Dhar, Zachary Chan, Giorgia Giordano, Jason X. Cheng, Hamed R. Youshanlouei, Anand A. Patel, Adam S. DuVall, Michael W. Drazer, Linda Kessler, Francis Burrows, Olatoyosi Odenike, Michael J. Thirman, Wendy Stock, Caner Saygin

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7172438862

Cites:

Cited by:

Related to: 10